So, we evaluated the difference in the half maximal inhibitory concentration (IC50) of some commonly used targeted chemotherapy agents between the STS patients with different TROAP expressions to provide a potential reference for drug therapy selection. The gene discussed is TROAP; the disease is telomere syndrome.